A Phase 2 interventional study of Sodium oligo-mannurarate 600mg and Sodium oligo-mannurarate 900mg in Alzheimer Disease and Cognitive Impairment, sponsored by Shanghai Greenvalley Pharmaceutical Co., Ltd.. Completed at 24 sites in China. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2015-01-27.
Sponsored by Shanghai Greenvalley Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 260 studies in Alzheimer Disease with a site in China — 150 open to participants now, 162 under way, 21 of them phase 3. Alzheimer Disease · China.
Among the 260 studies in Alzheimer Disease with a site in China, this one is the 44th largest by enrollment of the 176 interventional ones that give a count, is one of 4 that started in 2011, is one of 20 in phase 2, and was the 10th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.
Browse Alzheimer Disease studies →150 of the 260 studies in Alzheimer Disease with a site in China are open now. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18+
Hoffmann-La Roche · Sites in China, United States, Argentina and 7 more countries
Ages 55–80
Eli Lilly and Company · Sites in China, United States, Japan
Ages 18–85 · Healthy volunteers
Anhui Medical University · Sites in China
Ages 45–84
JYAMS PET Research & Development Limited · Sites in China
Ages 50+ · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 50 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
260 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 28 · Phase 3 36 · Phase 4 11
First in 2000; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 255 is above the median of 70 across 3,021 interventional studies indexed under Alzheimer Disease.
Median enrollment 100 across the 176 interventional studies, 566 across the 84 observational. Of the 65 that completed or were terminated, 16 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
68 of 260 have an industry lead sponsor. The 10 most frequent:
Shanghai Greenvalley Pharmaceutical Co., Ltd. is the lead sponsor of 5 studies on the registry; none are open to participants now.
Shanghai Greenvalley Pharmaceutical Co., Ltd. has 1 study filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
44 of the studies in Alzheimer Disease with a site in China that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT07422857Phase 3JYAMS PET Research & Development LimitedEvaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function | 2026-12-01 |
| NCT06126224Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | 2026-12-09 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT07323914Phase 3Xuanwu Hospital, BeijingClinical Analgesic Management in Dementia | 2027-01-01 |
Add all 44 to your calendar (.ics) → With an account.
Among the 260 studies in Alzheimer Disease with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to determine whether sodium oligo-mannurarate capsule is effective and safe in the treatment of mild to moderate alzheimer' disease, and to determine the best therapeutic dose of sodium oligo-mannurarate capsule.
Alzheimer's disease is known for placing a great burden on caregivers which includes social, psychological, physical or economic aspects. Research indicates that the disease is associated with plaques and tangles in the brain. Currently used treatments offer a small symptomatic benefit. No treatments to delay or halt the progression of the disease are, as of yet, available. The investigators suppose sodium oligo-mannurarate capsule to be effective to halt the progression of the disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Sodium oligo-mannurarate 900mg
Drug: Sodium oligo-mannurarate 600mg
Drug: Placebo
sodium oligo-mannurarate capsule 600mg twice a day for 24 weeks
Also known as: Sodium oligo-mannurarate low dose
sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks
Also known as: Sodium oligo-mannurarate high dose
simulant of sodium oligo-mannurarate capsule
Change of Alzheimer's Disease Assessment Scale-cognitive Subscale(ADAS-cog)/12 After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule
Alzheimer's Disease Assessment Scale-cognitive Subscale(ADAS-cog)/12 is the most popular cognitive testing instrument used in clinical trials. It consists of 12 tasks measuring the disturbances of memory, language, praxis, attention and other cognitive abilities which are often referred to as the core symptoms of AD. The total score ranges 0-75, the higher score indicates more severity of the disease. Change after 24 wks treatment was calculated by the week 24 minus week 0 (baseline), and a negative change represents an improvement.
Time frame: 24 weeks
Change of Clinician's Interview-Based Impression of Change Plus(CIBIC-plus) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule
Clinician's Interview-Based Impression of Change Plus(CIBIC-plus) is widely used in antidementia drug trials. It comprises Likert scales for disease severity and changes, and written accounts summarizing semistructured interviews evaluating behavior, cognition, and function. The results classified as 7 degrades as: Markedly improved, Moderately improved, Minimally improved, No change, Minimally worse, Moderately worse, and Markedly worse.
Time frame: 24 weeks
Change of Alzheimer's Disease Cooperative Study/Activities of Daily(ADCS-ADL) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule
Alzheimer's Disease Cooperative Study/Activities of Daily (ADCS-ADL) is a scale assessed the daily activties of AD patients after interviewed the caregiver. The scale mainly assess the eating, walking, writing, bathing and reading, et al of the subject. The total score ranges 0-78, the higher score indicate improvement in daily activities. Change after 24 wks treatment was calculated by the week 24 minus week 0 (baseline), and a positive change represents an improvement.
Time frame: 24 weeks
Change of Neuropsychiatric Inventory(NPI) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule
Neuropsychiatric Inventory (NPI) is a scale to obtain information on the presence of psychopathology in patient with brain disorders. The NPI was developed for application to patients with AD and other dementias, but it may be useful in the assessment of behavioral changes in other conditions. Twelve behavioral areas included in the NPI will be assessed in this trial: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety and elation/euphoria, et al. The total score ranges 0 to 120, the higher score indicates worse state of the AD patient. Change after 24wks treatmnt was calculated by the week 24 minus week 0 (baseline), and a negative change represents an improvement.
Time frame: 24 weeks
| Milestone | Sodium Oligo-mannurarate 900mg | Sodium Oligo-mannurarate 600mg | Placebo |
|---|---|---|---|
| Started | 86 | 84 | 85 |
| Completed | 75 | 70 | 78 |
| Not completed | 11 | 14 | 7 |
Alzheimer's Disease Assessment Scale-cognitive Subscale(ADAS-cog)/12 is the most popular cognitive testing instrument used in clinical trials. It consists of 12 tasks measuring the disturbances of memory, language, praxis, attention and other cognitive abilities which are often referred to as the core symptoms of AD. The total score ranges 0-75, the higher score indicates more severity of the disease. Change after 24 wks treatment was calculated by the week 24 minus week 0 (baseline), and a negative change represents an improvement.
| units on a scale | Sodium Oligo-mannurarate 900mg | Sodium Oligo-mannurarate 600mg | Placebo |
|---|---|---|---|
| Change of Alzheimer's Disease Assessment Scale-cognitive Subscale(ADAS-cog)/12 After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule | -2.58 ± 0.62 | -1.39 ± 0.75 | -1.45 ± 0.77 |
Clinician's Interview-Based Impression of Change Plus(CIBIC-plus) is widely used in antidementia drug trials. It comprises Likert scales for disease severity and changes, and written accounts summarizing semistructured interviews evaluating behavior, cognition, and function. The results classified as 7 degrades as: Markedly improved, Moderately improved, Minimally improved, No change, Minimally worse, Moderately worse, and Markedly worse.
| participants | Sodium Oligo-mannurarate 900mg | Sodium Oligo-mannurarate 600mg | Placebo |
|---|---|---|---|
| Markedly improved | 0 | 2 | 3 |
| Moderately improved | 13 | 9 | 6 |
| Minimally improved | 29 | 18 | 32 |
| No change | 35 | 23 | 25 |
| Minimally worse | 4 | 21 | 17 |
| Moderately worse | 2 | 3 | 0 |
| Markedly worse | 0 | 0 | 0 |
Alzheimer's Disease Cooperative Study/Activities of Daily (ADCS-ADL) is a scale assessed the daily activties of AD patients after interviewed the caregiver. The scale mainly assess the eating, walking, writing, bathing and reading, et al of the subject. The total score ranges 0-78, the higher score indicate improvement in daily activities. Change after 24 wks treatment was calculated by the week 24 minus week 0 (baseline), and a positive change represents an improvement.
| units on a scale | Sodium Oligo-mannurarate 900mg | Sodium Oligo-mannurarate 600mg | Placebo |
|---|---|---|---|
| Change of Alzheimer's Disease Cooperative Study/Activities of Daily(ADCS-ADL) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule | -0.49 ± 0.91 | -0.47 ± 0.88 | -1.06 ± 0.85 |
Neuropsychiatric Inventory (NPI) is a scale to obtain information on the presence of psychopathology in patient with brain disorders. The NPI was developed for application to patients with AD and other dementias, but it may be useful in the assessment of behavioral changes in other conditions. Twelve behavioral areas included in the NPI will be assessed in this trial: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety and elation/euphoria, et al. The total score ranges 0 to 120, the higher score indicates worse state of the AD patient. Change after 24wks treatmnt was calculated by the week 24 minus week 0 (baseline), and a negative change represents an improvement.
| units on a scale | Sodium Oligo-mannurarate 900mg | Sodium Oligo-mannurarate 600mg | Placebo |
|---|---|---|---|
| Change of Neuropsychiatric Inventory(NPI) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule | -1.11 ± 1.22 | 0.24 ± 0.83 | -2.08 ± 0.98 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sodium Oligo-mannurarate 900mg | — | 3/86 (3.5%) | 3/86 (3.5%) |
| Sodium Oligo-mannurarate 600mg | — | 6/84 (7.1%) | 12/84 (14.3%) |
| Placebo | — | 6/85 (7.1%) | 5/85 (5.9%) |
| Event | Sodium Oligo-mannurarate 900mg | Sodium Oligo-mannurarate 600mg | Placebo |
|---|---|---|---|
| Behavioral and psychiatric symptomsPsychiatric disorders | 0/86 | 1/84 | 0/85 |
| Subdural hematomaVascular disorders | 0/86 | 1/84 | 0/85 |
| Implantation of artificial heart pacemakerCardiac disorders | 0/86 | 1/84 | 0/85 |
| HerniaGeneral disorders | 0/86 | 1/84 | 0/85 |
| Compressive fracture of vertebraMusculoskeletal and connective tissue disorders | 0/86 | 1/84 | 0/85 |
| Lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/86 | 1/84 | 0/85 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/86 | 0/84 | 1/85 |
| StrokeNervous system disorders | 0/86 | 0/84 | 1/85 |
| Paralysis of oculomotor nerveNervous system disorders | 0/86 | 0/84 | 1/85 |
| AppendicitisGastrointestinal disorders | 0/86 | 0/84 | 1/85 |
| Event | Sodium Oligo-mannurarate 900mg | Sodium Oligo-mannurarate 600mg | Placebo |
|---|---|---|---|
| Psychiatiric disordersPsychiatric disorders | 0/86 | 5/84 | 0/85 |
| GastrointestinalGastrointestinal disorders | 1/86 | 0/84 | 4/85 |
| DermatologicSkin and subcutaneous tissue disorders | 1/86 | 2/84 | 0/85 |
| Ear and labyrinthEar and labyrinth disorders | 0/86 | 1/84 | 1/85 |
| Injuries, toxicosis, complications due to surgeryInjury, poisoning and procedural complications | 0/86 | 1/84 | 0/85 |
| Muscular and connective tissueMusculoskeletal and connective tissue disorders | 0/86 | 1/84 | 0/85 |
| CNS disordersNervous system disorders | 0/86 | 1/84 | 0/85 |
| Respiratoty system, chest and mediastinumRespiratory, thoracic and mediastinal disorders | 0/86 | 1/84 | 0/85 |
| Reproductive system and mammary glandReproductive system and breast disorders | 1/86 | 0/84 | 0/85 |
All the treated subjects were evaluated for safety. 2, 8 and 3 subjects were excluded from FAS in placebo, 600 mg and 900 mg group respectively. So the case No. were 83, 76, 83 for placebo, 600 mg and 900 mg group respectively.
| Age, Continuous(years) | Sodium Oligo-mannurarate 900mg | Sodium Oligo-mannurarate 600mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 70.39 ± 8.51 | 70.26 ± 8.40 | 70.34 ± 8.13 | 70.33 ± 8.24 |
| Sex: Female, Male(Participants) | Sodium Oligo-mannurarate 900mg | Sodium Oligo-mannurarate 600mg | Placebo | Total |
|---|---|---|---|---|
| Female | 50 | 41 | 52 | 143 |
| Male | 33 | 35 | 31 | 99 |
The record gives a start of Oct 2011, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2015, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Greenvalley Pharmaceutical Co., Ltd.